Literature DB >> 6362874

Therapeutic activity of mitoxantrone and ametantrone against murine tumors.

F M Schabel, T H Corbett, D P Griswold, W R Laster, M W Trader.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6362874     DOI： 10.1016/0305-7372(83)90017-8

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN： 0305-7372            Impact factor:   12.111


× No keyword cloud information.
  7 in total

Review 1.  Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer.

Authors:  D Faulds; J A Balfour; P Chrisp; H D Langtry
Journal:  Drugs       Date:  1991-03       Impact factor: 9.546

Review 2.  Pharmacokinetics and metabolism of mitoxantrone. A review.

Authors:  G Ehninger; U Schuler; B Proksch; K P Zeller; J Blanz
Journal:  Clin Pharmacokinet       Date:  1990-05       Impact factor: 6.447

3.  Comparative in vitro toxicity of mitoxantrone and adriamycin in human granulocyte-macrophage progenitor cells.

Authors:  H G Mergenthaler; P Brühl; G Ehninger; E Heidemann
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

4.  First-line combination chemotherapy with mitoxantrone and cyclophosphamide in advanced breast cancer.

Authors:  P Periti; G R della Cuna; F Pannuti; T Mazzei; P Preti; A Martoni; E Mini
Journal:  Invest New Drugs       Date:  1985       Impact factor: 3.850

5.  The pharmacokinetics and metabolism of mitoxantrone in man.

Authors:  G Ehninger; B Proksch; G Heinzel; E Schiller; K H Weible; D L Woodward
Journal:  Invest New Drugs       Date:  1985       Impact factor: 3.850

Review 6.  Mitoxantrone: a review of its pharmacological properties and use in acute nonlymphoblastic leukaemia.

Authors:  C J Dunn; K L Goa
Journal:  Drugs Aging       Date:  1996-08       Impact factor: 3.923

7.  Phase II evaluation of mitoxantrone plus cis-platinum in patients with advanced breast cancer. A Southwest Oncology Group study.

Authors:  J O Atiba; S J Green; H E Hynes; C K Osborne; T P Miller; M Davidner
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.